Pelthos Therapeutics Inc.

AMEX:PTHS

Biotechnology

Healthcare
$16.54 -1.28%

-$0.37 today

Market cap
$63.32M
Beta
3.13
P/E (TTM)
-0.7
EPS (TTM)
-$15.58
52W Low $16.50High $37.50

Volume 0.01M

Average 0.04M

PTHS Interest Expense

Cost of servicing the company's debt during the period.

Pelthos Therapeutics Inc.AMEX: PTHS

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense grows, but more slowly than its trailing trend

Q1 FY2026 interest expense of $2.35M rose 1660.8% year over year, behind the +1693.6% change in trailing-twelve-month interest expense. Sequentially, it rose 79.1% from the prior quarter. Over 3 fiscal years it compounded at +177.8% a year.

Context

  • Interest expense amounted to 17.9% of revenue in FY2025.
  • Interest expense increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1660.8% toward the trailing-twelve-month pace of +1693.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.35M+79.1% QoQ
Last fiscal yearDec 2025
$3.01M+283.0% YoY
LTMMar 2026
$5.23M+1693.6% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1660.8%——
1 year+283.0%——
3-year CAGR+177.8%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
3.01M USD
Year-over-year change
+283.0%
4-year CAGR
+944.6%

Interest Expense vs competitors

How PTHS compares with its peers on the latest reported figures

  • PTHS's LTM Mar 2026 interest expense of $5.23M is the highest of the 4 companies compared; the peer median is $0.
  • Its year-over-year change of +1693.6% is the highest of 4, against a peer median of -100.0%.
  • Interest expense amounts to 18.9% of revenue for PTHS.
PTHS Competitors Peer median
Interest Expense for PTHS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PTHSPelthos Therapeutics Inc.LTM Mar 2026$5.23M +1693.6%+177.8%18.9%
LIXTLixte Biotechnology Holdings, Inc.LTM Mar 2026$9.12K -28.6%+1.1%—
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025$0 -100.0%-86.5%—
CINGCingulate Inc.LTM Mar 2026-$1.36M -39019.1%+74.5%—
Peer median (excluding PTHS) $0-100.0%+1.1%—

Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000016.8M
Cost of Revenue00009.37M
Gross Profit00007.43M
Gross Margin————44.2%
Research & Development209.05K391.73K2.58M1.18M1.23M
Selling, General & Admin629.95K1.93M4.28M6.39M37.08M
Operating Expenses839K2.32M6.86M7.57M39.86M
Depreciation & Amortization00002.29M
EBITDA(595.13K)(2.32M)(6.86M)(7.17M)(45.41M)
EBITDA Margin————-270.4%
Operating Income(839K)(2.32M)(6.86M)(7.57M)(32.43M)
Operating Margin————-193.1%
Interest Income00005K
Interest Expense253140.43K518.51K786.39K3.01M
Other Income / Expenses243.61K(140.43K)(518.51K)(383.89K)(18.28M)
Income Before Tax(595.39K)(2.46M)(7.38M)(7.96M)(50.71M)
Pre-Tax Margin————-301.9%
Income Tax Expense0000(7.39M)
Net Income(595.39K)(2.46M)(7.38M)(7.96M)(43.32M)
Net Margin————-257.9%
EPS (Basic)(1.00)(4.26)(12.80)(13.54)(23.04)
EPS (Diluted)(1.00)(4.26)(12.80)(13.54)(23.04)
Weighted Avg Shares576.75K576.75K576.75K587.62K1.88M
Weighted Avg Shares (Diluted)576.75K576.75K576.75K587.62K1.88M

Pelthos Therapeutics Inc.

AMEX:PTHS

Intrinsic Alpha fair value

Locked

Current Price

$16.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.